Tags : ALPINE Study

Alkermes’ Reports Results of Aristada (aripiprazole lauroxil) and Invega Sustenna

Vartika Singh April 10, 2019

Shots: The P-IIIb ALPINE Study involves assessing of Aristada and Invega Sustenna in 200 patients experiencing an acute exacerbation of schizophrenia, followed by an outpatient phase for a total of […]readmore

Tags : ALPINE Study

Alkermes’ Reports Results of Aristada (aripiprazole lauroxil) and Invega Sustenna

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : ALPINE Study

﻿­Alkermes’ Reports Results of Aristada (aripiprazole lauroxil) and Invega Sustenna

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

Alkermes’ Reports Results of Aristada (aripiprazole lauroxil) and Invega Sustenna